It took a few months, but Cequent Pharmaceuticals--which is developing RNAi-based treatments--has completed its Series A round of financing with a total of $9 million. Cequent plans to go into the clinic next year with an experimental therapy for patients genetically predisposed to colon cancer. Ampersand Ventures, Nexus Medical Partners, and the Novartis Option Fund all took part in the round.
- see this release
- here's the report from Red Herring